{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:34:54Z","timestamp":1790969694536,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.bone.2021.115890","type":"journal-article","created":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T17:54:57Z","timestamp":1613930097000},"page":"115890","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["High persistence over two years with denosumab among postmenopausal women with osteoporosis in France: A prospective cohort study"],"prefix":"10.1016","volume":"146","author":[{"given":"Karine","family":"Briot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Schott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Vannak","family":"Chauny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Samama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"D\u00e9sam\u00e9ricq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2021.115890_bb0005","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/ncpendmet0941","article-title":"Selection of antiresorptive or anabolic treatments for postmenopausal osteoporosis","volume":"4","author":"Papapoulos","year":"2008","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.1016\/j.bone.2021.115890_bb0010","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.berh.2005.06.009","article-title":"Who will benefit from antiresorptive treatment (bisphosphonates)?","volume":"19","author":"Papapoulos","year":"2005","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.bone.2021.115890_bb0015","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/S0140-6736(06)68891-0","article-title":"Osteoporosis","volume":"367","author":"Sambrook","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2021.115890_bb0020","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2021.115890_bb0025","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.bone.2021.115890_bb0030","unstructured":"prolia_14122011_avis_ct10890.pdf."},{"key":"10.1016\/j.bone.2021.115890_bb0035","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jbspin.2018.02.009","article-title":"2018 update of French recommendations on the management of postmenopausal osteoporosis","volume":"85","author":"Briot","year":"2018","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.bone.2021.115890_bb0040","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00198-014-2871-6","article-title":"Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study","volume":"26","author":"Silverman","year":"2015","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2021.115890_bb0045","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1007\/s00198-015-3164-4","article-title":"Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study","volume":"26","author":"Hadji","year":"2015","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2021.115890_bb0050","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1007\/s00198-015-3253-4","article-title":"Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis","volume":"26","author":"Karlsson","year":"2015","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2021.115890_bb0055","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s12325-018-0779-9","article-title":"Real-world management of women with postmenopausal osteoporosis treated with Denosumab: a prospective observational study in the Czech Republic and Slovakia","volume":"35","author":"R\u016f\u017ei\u010dkov\u00e1","year":"2018","journal-title":"Adv. Ther."},{"key":"10.1016\/j.bone.2021.115890_bb0060","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s12325-019-00919-4","article-title":"Profile of women initiated on Denosumab and pattern of use in a restricted postmenopausal osteoporosis indication: a French database analysis over the period 2013\u20132014","volume":"36","author":"Emery","year":"2019","journal-title":"Adv. Ther."},{"key":"10.1016\/j.bone.2021.115890_bb0065","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00198-015-3234-7","article-title":"The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM extension study","volume":"26","author":"Papapoulos","year":"2015","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2021.115890_bb0070","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s00198-006-0171-5","article-title":"Persistence with teriparatide in patients with osteoporosis: the UK experience","volume":"17","author":"Arden","year":"2006","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2021.115890_bb0075","first-page":"2011","article-title":"Factors associated with persistence with teriparatide therapy: results from the DANCE Observational Study","author":"Gold","year":"2011","journal-title":"J Osteoporos"},{"key":"10.1016\/j.bone.2021.115890_bb0080","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1007\/s00198-011-1881-x","article-title":"Persistence with intravenous zoledronate in elderly patients with osteoporosis","volume":"23","author":"Lee","year":"2012","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2021.115890_bb0085","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/acr.21638","article-title":"Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population","volume":"64","author":"Curtis","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.bone.2021.115890_bb0090","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11657-017-0351-2","article-title":"Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium","volume":"12","author":"Fahrleitner-Pammer","year":"2017","journal-title":"Arch. Osteoporos."},{"key":"10.1016\/j.bone.2021.115890_bb0095","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11657-018-0491-z","article-title":"Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study","volume":"13","author":"Silverman","year":"2018","journal-title":"Arch. Osteoporos."},{"key":"10.1016\/j.bone.2021.115890_bb0100","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1007\/s00198-017-4080-6","article-title":"Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates","volume":"28","author":"Uebelhart","year":"2017","journal-title":"Osteoporosis Int"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328221000521?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328221000521?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:54:42Z","timestamp":1757613282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328221000521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":20,"alternative-id":["S8756328221000521"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2021.115890","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High persistence over two years with denosumab among postmenopausal women with osteoporosis in France: A prospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2021.115890","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115890"}}